---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342335"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-08-10T20:05:19+00:00"
generated_at: "2026-08-10T20:08:04.983374+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q2 2026 net loss $109.5M; TRUTAKNA approved and launched

## Summary
- Q2 2026 net loss $109.5M ($1.52/share) vs $76.5M ($1.20) in Q2 2025; cash $499.2M at June 30, 2026.
- FDA granted accelerated approval for TRUTAKNA in IgAN; first BAFF/APRIL inhibitor; U.S. launch underway.
- ORIGIN 3 final efficacy analysis expected Q3 2026; sBLA submission to FDA expected Q4 2026.
- Nancy Boman named Chief Regulatory Officer, succeeding William Turner upon his retirement in Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-342335
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-08-10T20:05:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/0001193125-26-342335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342335
- JSON: https://secwatch.observer/filing/0001193125-26-342335.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.